Keratoacanthoma
☆ Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
Yakajairika Keratoacanthoma
References
Keratoacanthoma (KA) ibundu reganda rinogara richizivikanwa nekukura kwaro nekukurumidza uye rinogona kudzoka rega. Zvinowanzoitika kune varume vakuru, vane ganda rakanaka vane nhoroondo yekukuvara kwezuva. Nepo kuvhiya kubviswa uchishandisa excision kana Mohs micrographic surgery kuri iko kurapwa kwakajairika, kune dzimwe nzira dzakasiyana dzekurapa dziripo.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) ibundu regiredhi yakaderera rinotanga mune mamwe maglands muganda uye rinotaridzika zvakafanana ne squamous cell carcinoma (SCC) pasi pemaikorosikopu. Pane gakava ririkuenderera mberi rekuti KA inofanira kuiswa sechimiro cheSCC inoparadza.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) ndiyo yechipiri yakajairika mhando yegomarara muvanhu, kunyanya pakati pevanhu vakuru. Kuvhiya kunowanzo shandiswa kurapa cSCC, asi kune vamwe varwere vasingakwanise kuvhiyiwa kana kusarudza kusadaro, dzimwe sarudzo senge intralesional treatments dzinogona kutariswa. Traditional intralesional treatments (methotrexate or 5-fluorouracil) yakashandiswa, asi pane tsvakiridzo irikuenderera mberi panzira itsva senge intralesional immunotherapy uye oncolytic virotherapy. Pano, isu tichatarisa akasiyana intralesional marapirwo ecSCC, kubva kumhando dzechinyakare kusvika kune yekucheka-kumucheto nzira.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Pasi pemaikorosikopu, keratoacanthoma yakada kufanana nesquamous cell carcinoma. Nepo vamwe vanoongorora zvirwere vachiisa keratoacanthoma sechinhu chakasiyana uye kwete chinokanganisa, inenge 6% yekiriniki uye histological keratoacanthoma inofambira mberi kune invasive uye hutsinye squamous cell cancers.
○ Kuongororwa uye Kurapwa
#Dermoscopy
#Skin biopsy